AGM Report

Report on AstraZeneca (AZN) AGM 2014

AGM Date: April 25, 2014

Report Author: Mark Bentley

Introduction

As a shareholder I am pleased to observe that the company appears to have advanced considerably since the last AGM, in line with the strategy explained at the time by the then newly appointed CEO, Pascal Soriot (PS). The market perceived the company as having severe problems due to a “cliff” of patent expiries, impacting future revenues and profits. Astra’s pipeline of new products, to replace revenues & profits from products with expiring patents, was perceived as weak. As disclosed in the annual report and in the quarterly Interim Management Statement (IMS) released on the morning of the AGM, there have been improvements on several fronts over the year, even though revenue, profits & EPS are all down significantly, as expected. The dividend, which made AZN an attractive ...

Not a member? Join today

Joining ShareSoc helps to empower our collective voice in representing investors, but we also offer exclusive benefits:

Member events & Masterclasses
Regular newsletter
Member only on-line Forums / Q&As
Company data and Voting Guidance
Educational resources
Get involved in our activities

Join now